- Home
- EMPD vs GANX Comparison
EMPD vs GANX Comparison
Compare EMPD & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMPD | GANX |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 76.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EMPD | GANX |
|---|---|---|
| Price | $3.20 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 294.5K | ★ 338.1K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.47 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $974,977.00 | $55,180.00 |
| Revenue This Year | $23.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $1.53 |
| 52 Week High | $8.10 | $4.34 |
Technical Indicators
Market Signals| Indicator | EMPD | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 37.42 |
| Support Level | $2.77 | $1.57 |
| Resistance Level | $3.22 | $1.85 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 76.84 | 6.70 |
Price Performance
Historical ComparisonAbout EMPD Empery Digital Inc.
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.